title: Epstein-Barr virus infection and lymphoproliferative disorder after hematopoietic cell transplantation.
abstract: Common herpes viruses such as Epstein-Barr virus (EBV) cause infection and disease after hematopoietic cell transplantation (HCT). Post-transplantation lymphoproliferative disorder following allogeneic HCT is a rare but life-threatening disease, mostly associated with EBV-infected B cells. Anti-CD20 monoclonal antibodies (e.g., rituximab) target normal and infected B cells and further suppress the patient's immune system. This article describes the development of cellular therapies by infusing virus-specific cytotoxic T lymphocytes via IV into patients to create an adoptive immune system for specific viral suppression.
authors.affiliation: University of Texas MD Anderson Cancer Center in Houston, USA. yazhen_z@yahoo.com
authors.forename: Yazhen
authors.initials: Y
authors.lastname: Zhong
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D018951:Antigens, CD20 / Q000276:immunology; D001402:B-Lymphocytes / Q000821:virology; D017690:Cell Transplantation; D020031:Epstein-Barr Virus Infections / Q000209:etiology* / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000209:etiology*; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000069283:Rituximab